Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Cost of Care
Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Opportunities to Optimize Cancer Policies Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement




Oct
12
Today In Oncology
Prior Authorization Is Burdensome for Patients, Resulting in Treatment Delays, Financial Strain, and Stress
Antidepressants May Improve Surgical Outcomes in Patients With GI Cancer and Depression
Patients Value Communication Skills From Cancer Surgeons Across Six Key Areas
Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer
Financial Toxicity Tied to Increased Risk of Mortality Among Patients With Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo